Prognostic Value of Post-Operative C-Reactive Protein-Based Inflammatory Biomarkers in Colorectal Cancer Patients: Systematic Review and Meta-Analysis

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• CancerNet. Colorectal cancer statistics; 2022. Available from: https://www.cancer.net/cancer-types/colorectal-cancer/statistics. Accessed July 13, 2022.
   Google Scholar
• Dolan RD, McSorley ST, Horgan PG, Laird B, McMillan DC. The role of the systemic inflammatory response in predicting outcomes in patients with advanced inoperable cancer: systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017;116:134–146. doi:10.1016/j.critrevonc.2017.06.002
   PubMed Web of Science ®Google Scholar
• Rossi S, Basso M, Strippoli A, et al. Are markers of systemic inflammation good prognostic indicators in colorectal cancer? Clin Colorectal Cancer. 2017;16(4):264–274. doi:10.1016/j.clcc.2017.03.015
   PubMed Web of Science ®Google Scholar
• Haruki K, Shiba H, Fujiwara Y, et al. Perioperative change in peripheral blood monocyte count may predict prognosis in patients with colorectal liver metastasis after hepatic resection. J Surg Oncol. 2012;106(1):31–35. doi:10.1002/jso.23033
   PubMed Web of Science ®Google Scholar
• Chan JCY, Diakos CI, Chan DLH, et al. A longitudinal investigation of inflammatory markers in colorectal cancer patients perioperatively demonstrates benefit in serial remeasurement. Ann Surg. 2018;267(6):1119–1125. doi:10.1097/SLA.0000000000002251
   PubMed Web of Science ®Google Scholar
• Li Z, Zhao R, Cui Y, Zhou Y, Wu X. The dynamic change of neutrophil to lymphocyte ratio can predict clinical outcome in stage I-III colon cancer. Sci Rep. 2018;8(1):9453. doi:10.1038/s41598-018-27896-y
   PubMedGoogle Scholar
• Matsuoka H, Ando K, Hu Q, et al. Postoperative C-reactive protein/albumin ratio is a biomarker of risk of recurrence and need for adjuvant chemotherapy for stage III colorectal cancer. Int J Clin Oncol. 2020;25(7):1318–1326. doi:10.1007/s10147-020-01672-3
   PubMed Web of Science ®Google Scholar
• Lin JX, Wang ZK, Huang YQ, et al. Dynamic changes in pre- and postoperative levels of inflammatory markers and their effects on the prognosis of patients with gastric cancer. J Gastrointest Surg. 2021;25(2):387–396. doi:10.1007/s11605-020-04523-8
   PubMed Web of Science ®Google Scholar
• Tan JW, Thiagarajan S, Zhou S, et al. ASO author reflections: postoperative inflammatory markers as a surveillance tool in colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2021;28(11):6636–6637. doi:10.1245/s10434-021-09733-1
   PubMed Web of Science ®Google Scholar
• Thiagarajan S, Tan JW, Zhou S, et al. Postoperative inflammatory marker surveillance in colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2021;28(11):6625–6635. doi:10.1245/s10434-020-09544-w
   PubMed Web of Science ®Google Scholar
• Yasui K, Shida D, Nakamura Y, Ahiko Y, Tsukamoto S, Kanemitsu Y. Postoperative, but not preoperative, inflammation-based prognostic markers are prognostic factors in stage III colorectal cancer patients. Br J Cancer. 2021;124(5):933–941. doi:10.1038/s41416-020-01189-6
   PubMed Web of Science ®Google Scholar
• Hiľovská L, Jendželovský R, Fedoročko P. Potency of non-steroidal anti-inflammatory drugs in chemotherapy. Mol Clin Oncol. 2015;3(1):3–12. doi:10.3892/mco.2014.446
   PubMed Web of Science ®Google Scholar
• Pantziarka P, Sukhatme V, Bouche G, Meheus L, Sukhatme VP. Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agent. Ecancermedicalscience. 2016;10:610. doi:10.3332/ecancer.2016.610
   PubMed Web of Science ®Google Scholar
• Zhang Z, Chen F, Shang L. Advances in antitumor effects of NSAIDs. Cancer Manag Res. 2018;10:4631–4640. doi:10.2147/CMAR.S175212
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Pietrocola F, Kroemer G. Nutrition, inflammation and cancer. Nat Immunol. 2017;18(8):843–850. doi:10.1038/ni.3754
   PubMed Web of Science ®Google Scholar
• Kaluza J, Håkansson N, Harris HR, Orsini N, Michaëlsson K, Wolk A. Influence of anti-inflammatory diet and smoking on mortality and survival in men and women: two prospective cohort studies. J Intern Med. 2019;285(1):75–91. doi:10.1111/joim.12823
   PubMed Web of Science ®Google Scholar
• Ugai T, Liu L, Tabung FK, et al. Prognostic role of inflammatory diets in colorectal cancer overall and in strata of tumor-infiltrating lymphocyte levels. Clin Transl Med. 2022;12(11):e1114. doi:10.1002/ctm2.1114
   PubMed Web of Science ®Google Scholar
• Johnson TV, Abbasi A, Owen-Smith A, et al. Postoperative better than preoperative C-reactive protein at predicting outcome after potentially curative nephrectomy for renal cell carcinoma. Urology. 2010;76(3):766.e761–765. doi:10.1016/j.urology.2010.01.052
   Web of Science ®Google Scholar
• Toiyama Y, Miki C, Inoue Y, Tanaka K, Mohri Y, Kusunoki M. Evaluation of an inflammation-based prognostic score for the identification of patients requiring postoperative adjuvant chemotherapy for stage II colorectal cancer. Exp Ther Med. 2011;2(1):95–101. doi:10.3892/etm.2010.175
   PubMed Web of Science ®Google Scholar
• Son W, Shin SJ, Park SH, et al. Clinical impact of combined modified Glasgow prognostic score and c-reactive protein/albumin ratio in patients with colorectal cancer. Diagnostics. 2020;10(11):859. doi:10.3390/diagnostics10110859
   Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89. doi:10.1186/s13643-021-01626-4
   PubMed Web of Science ®Google Scholar
• Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008–2012. doi:10.1001/jama.283.15.2008
   PubMed Web of Science ®Google Scholar
• Moons KGM, Hooft L, Williams K, Hayden JA, Damen J, Riley RD. Implementing systematic reviews of prognosis studies in Cochrane. Cochrane Database Syst Rev. 2018;(10). doi:10.1002/14651858.ED000129
   Web of Science ®Google Scholar
• Riley RD, Moons KGM, Snell KIE, et al. A guide to systematic review and meta-analysis of prognostic factor studies. BMJ. 2019;364:k4597. doi:10.1136/bmj.k4597
   PubMed Web of Science ®Google Scholar
• Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153–160. doi:10.1136/ebmental-2019-300117
   PubMed Web of Science ®Google Scholar
• Wigmore SJ, McMahon AJ, Sturgeon CM, Fearon KC. Acute-phase protein response, survival and tumour recurrence in patients with colorectal cancer. Br J Surg. 2001;88(2):255–260. doi:10.1046/j.1365-2168.2001.01669.x
   PubMed Web of Science ®Google Scholar
• McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg. 2003;90(2):215–219. doi:10.1002/bjs.4038
   PubMed Web of Science ®Google Scholar
• Crozier JE, McKee RF, McArdle CS, et al. Preoperative but not postoperative systemic inflammatory response correlates with survival in colorectal cancer. Br J Surg. 2007;94(8):1028–1032. doi:10.1002/bjs.5706
   PubMed Web of Science ®Google Scholar
• Leitch EF, Chakrabarti M, Crozier JE, et al. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer. 2007;97(9):1266–1270. doi:10.1038/sj.bjc.6604027
   PubMed Web of Science ®Google Scholar
• Guthrie GJ, Roxburgh CS, Farhan-Alanie OM, Horgan PG, McMillan DC. Comparison of the prognostic value of longitudinal measurements of systemic inflammation in patients undergoing curative resection of colorectal cancer. Br J Cancer. 2013;109(1):24–28. doi:10.1038/bjc.2013.330
   PubMed Web of Science ®Google Scholar
• McSorley ST, Watt DG, Horgan PG, McMillan DC. Postoperative systemic inflammatory response, complication severity, and survival following surgery for colorectal cancer. Ann Surg Oncol. 2016;23(9):2832–2840. doi:10.1245/s10434-016-5204-5
   PubMed Web of Science ®Google Scholar
• Watt DG, McSorley ST, Park JH, Horgan PG, McMillan DC. A postoperative systemic inflammation score predicts short- and long-term outcomes in patients undergoing surgery for colorectal cancer. Ann Surg Oncol. 2017;24(4):1100–1109. doi:10.1245/s10434-016-5659-4
   PubMed Web of Science ®Google Scholar
• McSorley ST, Tham A, Dolan RD, et al. Perioperative blood transfusion is associated with postoperative systemic inflammatory response and poorer outcomes following surgery for colorectal cancer. Ann Surg Oncol. 2020;27(3):833–843. doi:10.1245/s10434-019-07984-7
   PubMed Web of Science ®Google Scholar
• Shibutani M, Maeda K, Nagahara H, et al. The prognostic significance of a postoperative systemic inflammatory response in patients with colorectal cancer. World J Surg Oncol. 2015;13(1):194. doi:10.1186/s12957-015-0609-3
   PubMedGoogle Scholar
• Yamamoto M, Saito H, Uejima C, et al. Prognostic value of the combination of pre- and postoperative C-reactive protein in colorectal cancer patients. Surg Today. 2018;48(11):986–993. doi:10.1007/s00595-018-1689-9
   PubMed Web of Science ®Google Scholar
• Zhou ZQ, Pang S, Yu XC, et al. Predictive values of postoperative and dynamic changes of inflammation indexes in survival of patients with resected colorectal cancer. Curr Med Sci. 2018;38(5):798–808. doi:10.1007/s11596-018-1946-6
   PubMed Web of Science ®Google Scholar
• Matsubara D, Arita T, Nakanishi M, et al. The impact of postoperative inflammation on recurrence in patients with colorectal cancer. Int J Clin Oncol. 2019;25(4):602–613. doi:10.1007/s10147-019-01580-1
   PubMed Web of Science ®Google Scholar
• Li JJ, Zhang YW, Xu Q, et al. Systemic inflammatory markers of resectable colorectal cancer patients with different mismatch repair gene status. Cancer Manag Res. 2021;13:2925–2935. doi:10.2147/CMAR.S298885
   PubMed Web of Science ®Google Scholar
• Hua XW, Kratz M, Malen RC, et al. Association between post-treatment circulating biomarkers of inflammation and survival among stage II-III colorectal cancer patients. Br J Cancer. 2021;125(6):806–815. doi:10.1038/s41416-021-01458-y
   PubMed Web of Science ®Google Scholar
• Hermunen K, Soveri LM, Boisen MK, et al. Postoperative serum CA19-9, YKL-40, CRP and IL-6 in combination with CEA as prognostic markers for recurrence and survival in colorectal cancer. Acta Oncol. 2020;59(12):1416–1423. doi:10.1080/0284186X.2020.1800086
   PubMed Web of Science ®Google Scholar
• Osterman E, Mezheyeuski A, Sjoblom T, Glimelius B. Beyond the NCCN risk factors in colon cancer: an evaluation in a Swedish population-based cohort. Ann Surg Onc. 2020;27(4):1036–1045. doi:10.1245/s10434-019-08148-3
   PubMed Web of Science ®Google Scholar
• Lehtomaki K, Mustonen H, Kellokumpu-Lehtinen PL, et al. Lead time and prognostic role of serum CEA, CA19-9, IL-6, CRP, and YKL-40 after adjuvant chemotherapy in colorectal cancer. Cancers. 2021;13(15):3892. doi:10.3390/cancers13153892
   PubMed Web of Science ®Google Scholar
• Wesselink E, Balvers MGJ, Kok DE, et al. Levels of inflammation markers are associated with the risk of recurrence and all-cause mortality in patients with colorectal cancer. Cancer Epidem Biomar. 2021;30(6):1089–1099. doi:10.1158/1055-9965.EPI-20-1752
   PubMed Web of Science ®Google Scholar
• Seidu S, Kunutsor SK, Khunti K. Serum albumin, cardiometabolic and other adverse outcomes: systematic review and meta-analyses of 48 published observational cohort studies involving 1,492,237 participants. Scand Cardiovasc J. 2020;54(5):280–293. doi:10.1080/14017431.2020.1762918
   PubMed Web of Science ®Google Scholar
• Marques P, de Vries F, Dekkers OM, Korbonits M, Biermasz NR, Pereira AM. Serum inflammation-based scores in endocrine tumors. J Clin Endocrinol Metab. 2021;106(10):3796–3819. doi:10.1210/clinem/dgab238
   Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867. doi:10.1038/nature01322
   PubMed Web of Science ®Google Scholar
• Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27–41. doi:10.1016/j.immuni.2019.06.025
   PubMed Web of Science ®Google Scholar
• Terzić J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010;138(6):2101–2114. doi:10.1053/j.gastro.2010.01.058
   PubMed Web of Science ®Google Scholar
• Hart PC, Rajab IM, Alebraheem M, Potempa LA. C-reactive protein and cancer—diagnostic and therapeutic insights. Front Immunol. 2020;11(1):595835. doi:10.3389/fimmu.2020.595835
   PubMedGoogle Scholar
• Murdock JL, Duco MR, Reeves DJ. Tolerability of highly protein bound targeted oral oncolytic drugs in patients with hypoalbuminemia: a retrospective analysis. Ann Pharmacother. 2021;55(2):165–173. doi:10.1177/1060028020942485
   PubMed Web of Science ®Google Scholar
• Cho DS, Kim SI, Choo SH, Jang SH, Ahn HS, Kim SJ. Prognostic significance of modified Glasgow Prognostic Score in patients with non-metastatic clear cell renal cell carcinoma. Scand J Urol. 2016;50(3):186–191. doi:10.3109/21681805.2015.1136677
   PubMed Web of Science ®Google Scholar
• Hu X, Wang Y, Yang WX, Dou WC, Shao YX, Li X. Modified Glasgow prognostic score as a prognostic factor for renal cell carcinomas: a systematic review and meta-analysis. Cancer Manag Res. 2019;11(1):6163–6173. doi:10.2147/CMAR.S208839
   PubMedGoogle Scholar
• Tsujino T, Komura K, Hashimoto T, et al. C-reactive protein-albumin ratio as a prognostic factor in renal cell carcinoma - a data from multi-institutional study in Japan. Urol Oncol. 2019;37(11):812.e811–812.e818. doi:10.1016/j.urolonc.2019.04.002
   Web of Science ®Google Scholar
• Matsuda S, Niihara M, Tsubosa Y, et al. Clinical significance of postoperative recovery of serum albumin levels in patients with esophageal cancer who underwent transthoracic esophagectomy. Surg Today. 2016;46(10):1138–1145. doi:10.1007/s00595-015-1300-6
   PubMed Web of Science ®Google Scholar
• Matsunaga T, Miyata H, Sugimura K, et al. Prognostic significance of C-reactive protein-to-prealbumin ratio in patients with esophageal cancer. Yonago Acta Med. 2020;63(1):8–19. doi:10.33160/yam.2020.02.002
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Ikeda Y, Korenaga D, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer. 2005;103(9):1856–1864. doi:10.1002/cncr.20976
   PubMed Web of Science ®Google Scholar
• Ito T, Shinkawa H, Takemura S, et al. Impact of the preoperative C-reactive protein to albumin ratio on the long-term outcomes of hepatic resection for intrahepatic cholangiocarcinoma. Asian Pac J Cancer Prev. 2020;21(8):2373–2379. doi:10.31557/APJCP.2020.21.8.2373
   PubMedGoogle Scholar
• He S, Wang Y, Chen H, et al. C-Reactive Protein/Albumin Ratio (CAR) as a prognostic factor in patients with non-metastatic nasopharyngeal carcinoma. J Cancer. 2016;7(15):2360–2366. doi:10.7150/jca.16443
   PubMed Web of Science ®Google Scholar
• El Iskandarani M, El Kurdi B, Murtaza G, Paul TK, Refaat MM. Prognostic role of albumin level in heart failure: a systematic review and meta-analysis. Medicine. 2021;100(10):e24785. doi:10.1097/MD.0000000000024785
   PubMed Web of Science ®Google Scholar
• Hong Z, Jiang Y, Liu P, Zhang L. Association of microalbuminuria and adverse outcomes in hypertensive patients: a meta-analysis. Int Urol Nephrol. 2021;53(11):2311–2319. doi:10.1007/s11255-021-02795-w
   PubMed Web of Science ®Google Scholar
• Izcovich A, Ragusa MA, Tortosa F, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: a systematic review. PLoS One. 2020;15(11):e241955. doi:10.1371/journal.pone.0241955
   PubMed Web of Science ®Google Scholar
• Soetedjo NNM, Iryaningrum MR, Damara FA, et al. Prognostic properties of hypoalbuminemia in COVID-19 patients: a systematic review and diagnostic meta-analysis. Clin Nutr ESPEN. 2021;45:120–126. doi:10.1016/j.clnesp.2021.07.003
   PubMed Web of Science ®Google Scholar
• Wang F, Ao G, Wang Y, et al. Risk factors for mortality in hemodialysis patients with COVID-19: a systematic review and meta-analysis. Ren Fail. 2021;43(1):1394–1407. doi:10.1080/0886022X.2021.1986408
   PubMed Web of Science ®Google Scholar
• Wu Y, Li H, Zhang Z, et al. Risk factors for mortality of coronavirus disease 2019 (COVID-19) patients during the early outbreak of COVID-19: a systematic review and meta-analysis. Ann Palliat Med. 2021;10(5):5069–5083. doi:10.21037/apm-20-2557
   PubMed Web of Science ®Google Scholar
• Zinellu A, Mangoni AA. Serum complement C3 and C4 and COVID-19 severity and mortality: a systematic review and meta-analysis with meta-regression. Front Immunol. 2021;12(1):696085. doi:10.3389/fimmu.2021.696085
   PubMedGoogle Scholar
• Ma L, Zhao S. Risk factors for mortality in patients undergoing hemodialysis: a systematic review and meta-analysis. Int J Cardiol. 2017;238(1):151–158. doi:10.1016/j.ijcard.2017.02.095
   PubMedGoogle Scholar
• Ashour AA, Atta MA, Sadek KW, et al. Albumin administration in patients with decompensated liver cirrhosis: a meta-analytic update. Eur J Gastroenterol Hepatol. 2021;33(4):479–486. doi:10.1097/MEG.0000000000001932
   PubMed Web of Science ®Google Scholar
• Is B, Bombassaro IZ, Tovo CV, et al. Albumin in the management of hepatic encephalopathy: a systematic review and meta-analysis. Ann Hepatol. 2021;26(1):100541. doi:10.1016/j.aohep.2021.100541
   PubMedGoogle Scholar
• Shrestha DB, Budhathoki P, Sedhai YR, et al. Safety and efficacy of human serum albumin treatment in patients with cirrhotic ascites undergoing paracentesis: a systematic review and meta-analysis. Ann Hepatol. 2021;26(1):100547. doi:10.1016/j.aohep.2021.100547
   PubMedGoogle Scholar
• Teh KB, Loo JH, Tam YC, Wong YJ. Efficacy and safety of albumin infusion for overt hepatic encephalopathy: a systematic review and meta-analysis. Dig Liver Dis. 2021;53(7):817–823. doi:10.1016/j.dld.2021.04.030
   PubMedGoogle Scholar
• Kudarha RR, Sawant KK. Albumin based versatile multifunctional nanocarriers for cancer therapy: fabrication, surface modification, multimodal therapeutics and imaging approaches. Mater Sci Eng C. 2017;81(1):607–626. doi:10.1016/j.msec.2017.08.004
   PubMedGoogle Scholar
• Azab B, Camacho-Rivera M, Taioli E. Average values and racial differences of neutrophil lymphocyte ratio among a nationally representative sample of United States subjects. PLoS One. 2014;9(11):e112361. doi:10.1371/journal.pone.0112361
   PubMed Web of Science ®Google Scholar